Imperial College London
Alternate

Professor Toby Maher

Faculty of Medicine, National Heart & Lung Institute

Professor of Interstitial Lung Disease
 
 
 
//

Contact

 

+44 (0)20 7594 2151t.maher

 
 
//

Assistant

 

Ms Georgina Moss +44 (0)20 7594 2151

 
//

Location

 

364Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Corte:2021:10.1136/bmjresp-2021-001026,
author = {Corte, TJ and Lancaster, L and Swigris, JJ and Maher, TM and Goldin, JG and Palmer, SM and Suda, T and Ogura, T and Minnich, A and Zhan, X and Tirucherai, GS and Elpers, B and Xiao, H and Watanabe, H and Smith, RA and Charles, ED and Fischer, A},
doi = {10.1136/bmjresp-2021-001026},
journal = {BMJ OPEN RESPIRATORY RESEARCH},
title = {Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)},
url = {http://dx.doi.org/10.1136/bmjresp-2021-001026},
volume = {8},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AU  - Corte,TJ
AU  - Lancaster,L
AU  - Swigris,JJ
AU  - Maher,TM
AU  - Goldin,JG
AU  - Palmer,SM
AU  - Suda,T
AU  - Ogura,T
AU  - Minnich,A
AU  - Zhan,X
AU  - Tirucherai,GS
AU  - Elpers,B
AU  - Xiao,H
AU  - Watanabe,H
AU  - Smith,RA
AU  - Charles,ED
AU  - Fischer,A
DO  - 10.1136/bmjresp-2021-001026
PY  - 2021///
TI  - Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
T2  - BMJ OPEN RESPIRATORY RESEARCH
UR  - http://dx.doi.org/10.1136/bmjresp-2021-001026
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000736696500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL  - 8
ER  -
Download